Table 1.
Baseline patient demographics and characteristics
| Variable | nab-Paclitaxel (N = 264) | Dacarbazine (N = 265) | All patients (N = 529) |
|---|---|---|---|
| Age | |||
| Median years (min, max) | 62 (21, 85) | 64 (28, 87) | 63 (21, 87) |
| <65, n (%) | 154 (58) | 135 (51) | 289 (55) |
| Sex | |||
| Male, n (%) | 173 (66) | 174 (66) | 347 (66) |
| Region | |||
| North America, n (%) | 115 (44) | 116 (44) | 231 (44) |
| Western Europe, n (%) | 114 (43) | 114 (43) | 228 (43) |
| Australia, n (%) | 35 (13) | 35 (13) | 70 (13) |
| Ethnicity | |||
| White, n (%) | 251 (95) | 252 (95) | 503 (95) |
| Latino, n (%) | 12 (5) | 12 (5) | 24 (95) |
| Asian, n (%) | 1 (<1) | 1 (<1) | 2 (<1) |
| ECOG PS | |||
| 0, n (%) | 195 (74) | 181 (68) | 367 (71) |
| 1, n (%) | 68 (26) | 82 (31) | 150 (28) |
| 2, n (%) | 1 (<1) | 2 (<1) | 3 (<1) |
| Metastatic stage | |||
| M1a, n (%) | 27 (10) | 21 (8) | 48 (9) |
| M1b, n (%) | 66 (25) | 69 (26) | 135 (26) |
| M1c, n (%) | 171 (65) | 175 (66) | 346 (65) |
| LDH category | |||
| <0.8× ULN, n (%) | 138 (52) | 139 (52) | 277 (52) |
| 0.8–1.1× ULN, n (%) | 72 (27) | 69 (26) | 141 (27) |
| >1.1–2× ULN, n (%) | 51 (19) | 56 (21) | 107 (20) |
| >2× ULN, n (%) | 3 (1) | 1 (<1) | 4 (<1) |
| BRAF status | |||
| Known, n (%) | 181 (69) | 175 (66) | 356 (67) |
| Mutant | 65 (36) | 67 (38) | 132 (37) |
| Wild type | 116 (64) | 108 (62) | 224 (63) |
| Unknown, n (%) | 83 (31) | 90 (34) | 173 (33) |
| Prior therapy | |||
| Metastatic, n (%) | 18 (7) | 24 (9) | 42 (8) |
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PS, performance status; ULN, upper limit of normal.